Contemporary management of lower urinary tract disease with botulinum toxin a: A systematic review of Botox (onabotulinumtoxinA) and Dysport (abobotulinumtoxinA)

European Urology

Volumn 60, Issue 4, 2011, Pages 784-795

  Mangera, Altaf ^a   Andersson, Karl Erik ^b   Apostolidis, Apostolos ^c   Chapple, Chris ^a   Dasgupta, Prokar ^d   Giannantoni, Antonella ^e   Gravas, Stavros ^f   Madersbacher, Stephan ^g  

^a SHEFFIELD TEACHING HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^b WAKE FOREST SCHOOL OF MEDICINE   (United States)

^c ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^d GUY S HOSPITAL   (United Kingdom)

^e UNIVERSITY OF PERUGIA   (Italy)

^f UNIVERSITY OF THESSALY   (Greece)

^g Donauspital ^*  (Austria)

Author keywords

AbobotulinumtoxinA; Bladder outflow obstruction; Botox; Botulinum toxin; Detrusor sphincter dyssynergia; Dysport; Idiopathic detrusor overactivity; Neurogenic detrusor overactivity; OnabotulinumtoxinA; Painful bladder syndrome

Indexed keywords

BOTULINUM TOXIN A; PLACEBO;

BLADDER NECK STENOSIS; CLINICAL TRIAL; DETRUSOR DYSSYNERGIA; HEMATURIA; HUMAN; HYPOASTHENIA; IDIOPATHIC DETRUSOR OVERACTIVITY; INJECTION SITE PAIN; INTERSTITIAL CYSTITIS; LOWER URINARY TRACT SYMPTOM; MUSCLE WEAKNESS; NEUROGENIC DETRUSOR OVERACTIVITY; OVERACTIVE BLADDER; PAINFUL BLADDER SYNDROME; PRIORITY JOURNAL; REVIEW; STRESS INCONTINENCE; SYSTEMATIC REVIEW; TREATMENT OUTCOME; XEROSTOMIA;

BOTULINUM TOXINS, TYPE A; FEMALE; HUMANS; LOWER URINARY TRACT SYMPTOMS; MALE; NEUROTOXINS; TREATMENT OUTCOME; UROLOGIC DISEASES;

EID: 80052264107     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.07.001     Document Type: Review

References (76)

1. D.D. Dykstra, A.A. Sidi, A.B. Scott, J.M. Pagel, and G.D. Goldish Effects of botulinum A toxin on detrusor-sphincter dyssynergia in spinal cord injury patients J Urol 139 1988 919 922
2. B. Schurch, D.M. Schmid, and M. Stohrer Treatment of neurogenic incontinence with botulinum toxin A N Engl J Med 342 2000 665 (Pubitemid 30118430)
3. H.C. Kuo Urodynamic evidence of effectiveness of botulinum A toxin injection in treatment of detrusor overactivity refractory to anticholinergic agents Urology 63 2004 868 872
4. G. Maria, G. Brisinda, I.M. Civello, A.R. Bentivoglio, G. Sganga, and A. Albanese Relief by botulinum toxin of voiding dysfunction due to benign prostatic hyperplasia: results of a randomized, placebo-controlled study Urology 62 2003 259 264 (Pubitemid 36952073)
5. C.P. Smith, P. Radziszewski, A. Borkowski, G.T. Somogyi, T.B. Boone, and M.B. Chancellor Botulinum toxin a has antinociceptive effects in treating interstitial cystitis Urology 64 2004 871 875 (Pubitemid 39469494)
6. C. Montecucco, and J. Molgo Botulinal neurotoxins: revival of an old killer Curr Opin Pharmacol 5 2005 274 279 (Pubitemid 40674251)
7. A. Coelho, P. Dinis, and R. Pinto Distribution of the high-affinity binding site and intracellular target of botulinum toxin type A in the human bladder Eur Urol 57 2010 884 890
8. M. Harper, C.J. Fowler, and P. Dasgupta Botulinum toxin and its applications in the lower urinary tract BJU Int 93 2004 702 706 (Pubitemid 38497013)
9. T. Leippold, A. Reitz, and B. Schurch Botulinum toxin as a new therapy option for voiding disorders: current state of the art Eur Urol 44 2003 165 174 (Pubitemid 36916999)
10. J. Grosse, G. Kramer, and M. Stöhrer Success of repeat detrusor injections of botulinum a toxin in patients with severe neurogenic detrusor overactivity and incontinence Eur Urol 47 2005 653 659 (Pubitemid 40521915)
11. G. Maria, F. Cadeddu, D. Brisinda, F. Brandara, and G. Brisinda Management of bladder, prostatic and pelvic floor disorders with botulinum neurotoxin Curr Med Chem 12 2005 247 265 (Pubitemid 40305618)
12. D. Dressler Comparing Botox and Xeomin for axillar hyperhidrosis J Neural Transm 117 2010 317 319
13. C.M. Gomes, J.E. de Castro Filho, and R.F. Rejowski Experience with different botulinum toxins for the treatment of refractory neurogenic detrusor overactivity Int Braz J Urol 36 2010 66 74
14. R. Wenzel, D. Jones, and J.A. Borrego Comparing two botulinum toxin type A formulations using manufacturers' product summaries J Clin Pharm Ther 32 2007 387 402 (Pubitemid 47063164)
15. R.G. Wenzel Pharmacology of botulinum neurotoxin serotype A Am J Health Syst Pharm 61 2004 S5 S10
16. D. Moher, A. Liberati, J. Tetzlaff, and D.G. Altman Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement BMJ 339 2009 b2535
17. G. Del Popolo, M.T. Filocamo, and V. Li Marzi Neurogenic detrusor overactivity treated with english botulinum toxin A: 8-year experience of one single centre Eur Urol 53 2008 1013 1020 (Pubitemid 351434489)
18. A. Sahai, C. Dowson, M.S. Khan, and P. Dasgupta Repeated injections of botulinum toxin-A for idiopathic detrusor overactivity Urology 75 2010 552 558
19. A. Apostolidis, P. Dasgupta, and P. Denys Recommendations on the use of botulinum toxin in the treatment of lower urinary tract disorders and pelvic floor dysfunctions: a European consensus report Eur Urol 55 2009 100 120
20. I. Ehren, D. Volz, and E. Farrelly Efficacy and impact of botulinum toxin A on quality of life in patients with neurogenic detrusor overactivity: a randomised, placebo-controlled, double-blind study Scand J Urol Nephrol 41 2007 335 340 (Pubitemid 47357195)
21. P. Grise, A. Ruffion, P. Denys, G. Egon, and E. Chartier Kastler Efficacy and tolerability of botulinum toxin type A in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses Eur Urol 58 2010 759 766
22. J. Grosse, G. Kramer, and G. Jakse Comparing two types of botulinum-A toxin detrusor injections in patients with severe neurogenic detrusor overactivity: a case-control study BJU Int 104 2009 651 656
23. B. Schurch, M. de Seze, and P. Denys Botulinum toxin type a is a safe and effective treatment for neurogenic urinary incontinence: results of a single treatment, randomized, placebo controlled 6-month study J Urol 174 2005 196 200 (Pubitemid 40825713)
24. B. Schurch, P. Denys, C.M. Kozma, P.R. Reese, T. Slaton, and R.L. Barron Botulinum toxin A improves the quality of life of patients with neurogenic urinary incontinence Eur Urol 52 2007 850 859 (Pubitemid 47126174)
25. A. Giannantoni, S.M. Di Stasi, R.L. Stephen, V. Bini, E. Costantini, and M. Porena Intravesical resiniferatoxin versus botulinum-A toxin injections for neurogenic detrusor overactivity: a prospective randomized study J Urol 172 2004 240 243
26. T.A. Abdel-Meguid Botulinum toxin-A injections into neurogenic overactive bladder - to include or exclude the trigone? A prospective, randomized, controlled trial J Urol 184 2010 2423 2428
27. F. Cruz, S. Herschorn, and J. Heesakkers Efficacy and safety of onabotulinumtoxinA in patients with urinary incontinence due to neurogenic deterusor overactivity [abstract 579] Eur Urol Suppl 10 2011 190
28. S.D. Apkon, and D. Cassidy Safety considerations in the use of botulinum toxins in children with cerebral palsy PM R 2 2010 282 284
29. Early communication about an ongoing safety review of Botox and Botox Cosmetic (botulinum toxin type A) and Myobloc (botulinum toxin type B). US Food and Drug Administration Web site. http://www.fda.gov/Drugs/DrugSafety/ PostmarketDrugSafetyInformationforPatientsandProviders/ DrugSafetyInformationforHeathcareProfessionals/ucm070366.htm
30. L. Brubaker, H.E. Richter, and A. Visco Refractory idiopathic urge urinary incontinence and botulinum A injection J Urol 180 2008 217 222
31. M.K. Flynn, C.L. Amundsen, M. Perevich, F. Liu, and G.D. Webster Outcome of a randomized, double-blind, placebo controlled trial of botulinum A toxin for refractory overactive bladder J Urol 181 2009 2608 2615
32. A. Sahai, M.S. Khan, and P. Dasgupta Efficacy of botulinum toxin-A for treating idiopathic detrusor overactivity: results from a single center, randomized, double-blind, placebo controlled trial J Urol 177 2007 2231 2236 (Pubitemid 46726400)
33. R. Dmochowski, C. Chapple, and V.W. Nitti Efficacy and safety of onabotulinumtoxinA for idiopathic overactive bladder: a double-blind, placebo controlled, randomized, dose ranging trial J Urol 184 2010 2416 2422
34. D.G. Tincello, M.C. Slack, and S. Kenyon Botulinum toxin-A for refractory detrusor overactivity in women: a 240 patient randomised placebo controlled trial [abstract 581] Eur Urol Suppl 10 2011 191
35. M. Marberger, B. Egerdie, and E. Chartier-Kastler A randomized placebo-controlled dose finding study of onabotulinumtoixnA in men with BPH [abstract 325] Eur Urol Suppl 10 2011 119
36. J. Silva, C. Silva, and L. Saraiva Intraprostatic botulinum toxin type A injection in patients unfit for surgery presenting with refractory urinary retention and benign prostatic enlargement. Effect on prostate volume and micturition resumption Eur Urol 53 2008 153 159 (Pubitemid 350166733)
37. J. Silva, R. Pinto, and T. Carvalho Intraprostatic botulinum toxin type A injection in patients with benign prostatic enlargement: duration of the effect of a single treatment BMC Urol 9 2009 9
38. J. Silva, R. Pinto, and T. Carvalho Intraprostatic botulinum toxin type A administration: evaluation of the effects on sexual function BJU Int 107 2011 1950 1954
39. H.C. Kuo, and H.T. Liu Therapeutic effects of add-on botulinum toxin A on patients with large benign prostatic hyperplasia and unsatisfactory response to combined medical therapy Scand J Urol Nephrol 43 2009 206 211
40. D.S. Park, T.W. Cho, Y.K. Lee, Y.T. Lee, Y.K. Hong, and W.K. Jang Evaluation of short term clinical effects and presumptive mechanism of botulinum toxin type A as a treatment modality of benign prostatic hyperplasia Yonsei Med J 47 2006 706 714 (Pubitemid 44697302)
41. M. Nikoobakht, A. Daneshpajooh, and H. Ahmadi Intraprostatic botulinum toxin type A injection for the treatment of benign prostatic hyperplasia: Initial experience with Dysport Scand J Urol Nephrol 44 2010 151 157
42. P. Gallien, J.M. Reymann, G. Amarenco, B. Nicolas, M. de Seze, and E. Bellissant Placebo controlled, randomised, double blind study of the effects of botulinum A toxin on detrusor sphincter dyssynergia in multiple sclerosis patients J Neurol Neurosurg Psychiatry 76 2005 1670 1676 (Pubitemid 41697632)
43. H.P. Gottsch, J.L. Miller, C.C. Yang, and R.E. Berger A pilot study of botulinum toxin for interstitial cystitis/painful bladder syndrome Neurourol Urodyn 30 2011 93 96
44. H.C. Kuo, and M.B. Chancellor Comparison of intravesical botulinum toxin type A injections plus hydrodistention with hydrodistention alone for the treatment of refractory interstitial cystitis/painful bladder syndrome BJU Int 104 2009 657 661
45. H. Schulte-Baukloh, J. Schobert, T. Stolze, B. Sturzebecher, C. Weiss, and H.H. Knispel Efficacy of botulinum-A toxin bladder injections for the treatment of neurogenic detrusor overactivity in multiple sclerosis patients: an objective and subjective analysis Neurourol Urodyn 25 2006 110 115
46. I.F. Ghalayini, M.A. Al-Ghazo, and Z.A. Elnasser Is efficacy of repeated intradetrusor botulinum toxin type A (Dysport) injections dose dependent?. Clinical and urodynamic results after four injections in patients with drug-resistant neurogenic detrusor overactivity Int Urol Nephrol 41 2009 805 813
47. F. Mascarenhas, M. Cocuzza, C.M. Gomes, and N. Leao Trigonal injection of botulinum toxin-A does not cause vesicoureteral reflux in neurogenic patients Neurourol Urodyn 27 2008 311 314 (Pubitemid 351656402)
48. R.P. Manecksha, I.M. Cullen, and S. Ahmad Prospective randomized controlled trial compering trigonal versus trigone-sparing intradetrusor injection of botulinum toxin A for refractory idiopathic detrusor overactivity [abstract 580] Eur Urol Suppl 10 2011 191
49. A. Lucioni, D.E. Rapp, E.M. Gong, P. Fedunok, and G.T. Bales Intravesical botulinum type A toxin injection in patients with overactive bladder: trigone versus trigone-sparing injection Can J Urol 13 2006 3291 3295
50. H.C. Kuo Comparison of effectiveness of detrusor, suburothelial and bladder base injections of botulinum toxin a for idiopathic detrusor overactivity J Urol 178 2007 1359 1363
51. H.C. Kuo Clinical effects of suburothelial injection of botulinum A toxin on patients with nonneurogenic detrusor overactivity refractory to anticholinergics Urology 66 2005 94 98
52. S. Reddy, A. Chawla, and J. Thomas Botulinum toxin in high-risk BPH patients in retention Indian J Urol 24 2008 276
53. J.J. Wyndaele, and S.A. Van Dromme Muscular weakness as side effect of botulinum toxin injection for neurogenic detrusor overactivity Spinal Cord 40 2002 599 600 (Pubitemid 35305668)
54. K. De Laet, and J.J. Wyndaele Adverse events after botulinum A toxin injection for neurogenic voiding disorders Spinal Cord 43 2005 397 399 (Pubitemid 41039538)
55. J. Pannek, K. Gocking, and U. Bersch Long-term effects of repeated intradetrusor botulinum neurotoxin A injections on detrusor function in patients with neurogenic bladder dysfunction BJU Int 104 2009 1246 1250
56. V. Kalsi, G. Gonzales, and R. Popat Botulinum injections for the treatment of bladder symptoms of multiple sclerosis Ann Neurol 62 2007 452 457 (Pubitemid 350308769)
57. M. Akbar, R. Abel, and T.M. Seyler Repeated botulinum-A toxin injections in the treatment of myelodysplastic children and patients with spinal cord injuries with neurogenic bladder dysfunction BJU Int 100 2007 639 645 (Pubitemid 47205449)
58. P. Patki, J.B. Woodhouse, K. Patil, R. Hamid, and J. Shah An effective day case treatment combination for refractory neuropathic mixed incontinence Int Braz J Urol 34 2008 63 71
59. A. Ruffion, O. Capelle, P. Paparel, B. Leriche, A. Leriche, and P. Grise What is the optimum dose of type A botulinum toxin for treating neurogenic bladder overactivity? BJU Int 97 2006 1030 1034
60. R.M. Bauer, C. Gratzke, and A. Roosen Patient-reported side effects of intradetrusor botulinum toxin type A for idiopathic overactive bladder syndrome Urol Int 86 2011 68 72
61. M. Stoehrer, A. Wolff, and G. Kramer Treatment of neurogenic detrusor overactivity with botulinum toxin A: the first seven years Urol Int 83 2009 379 385
62. H. Schulte-Baukloh, H. Bigalke, and K. Miller Botulinum neurotoxin type A in urology: antibodies as a cause of therapy failure Int J Urol 15 2008 407 415 (Pubitemid 351623889)
63. A.M. Kajbafzadeh, L. Nikfarjam, A.H. Mahboubi, and S. Dianat Antibody formation following botulinum toxin type A (Dysport) injection in children with intractable bladder hyper-reflexia Urology 76 2010 233 237
64. A. Apostolidis, T.S. Jacques, and A. Freeman Histological changes in the urothelium and suburothelium of human overactive bladder following intradetrusor injections of botulinum neurotoxin type A for the treatment of neurogenic or idiopathic detrusor overactivity Eur Urol 53 2008 1245 1253
65. E. Compérat, A. Reitz, A. Delcourt, F. Capron, P. Denys, and E. Chartier-Kastler Histologic features in the urinary bladder wall affected from neurogenic overactivity - a comparison of inflammation, oedema and fibrosis with and without injection of botulinum toxin type A Eur Urol 50 2006 1058 1064 (Pubitemid 44486475)
66. A. Haferkamp, B. Schurch, and A. Reitz Lack of ultrastructural detrusor changes following endoscopic injection of botulinum toxin type A in overactive neurogenic bladder Eur Urol 46 2004 784 791 (Pubitemid 39488414)
67. B.L. Cohen, P. Barboglio, D. Rodriguez, and A.E. Gousse Preliminary results of a dose-finding study for botulinum toxin-A in patients with idiopathic overactive bladder: 100 versus 150 units Neurourol Urodyn 28 2009 205 208
68. I.F. Ghalayini, and M.A. Al-Ghazo Intradetrusor injection of botulinum-A toxin in patients with idiopathic and neurogenic detrusor overactivity: urodynamic outcome and patient satisfaction Neurourol Urodyn 26 2007 531 536 (Pubitemid 47036140)
69. S. Jeffery, M. Fynes, F. Lee, K. Wang, L. Williams, and R. Morley Efficacy and complications of intradetrusor injection with botulinum toxin A in patients with refractory idiopathic detrusor overactivity BJU Int 100 2007 1302 1306 (Pubitemid 350043916)
70. T.M. Kessler, S. Khan, J. Panicker, A. Roosen, S. Elneil, and C.J. Fowler Clean intermittent self-catheterization after botulinum neurotoxin type A injections: short-term effect on quality of life Obstet Gynecol 113 2009 1046 1051
71. M. De Seze, H. Petit, and P. Gallien Botulinum a toxin and detrusor sphincter dyssynergia: a double-blind lidocaine-controlled study in 13 patients with spinal cord disease Eur Urol 42 2002 56 62 (Pubitemid 35339646)
72. H. Petit, L. Wiart, and E. Gaujard Botulinum A toxin treatment for detrusor-sphincter dyssynergia in spinal cord disease Spinal Cord 36 1998 91 94 (Pubitemid 28059487)
73. D.D. Dykstra, and A.A. Sidi Treatment of detrusor-sphincter dyssynergia with botulinum A toxin: a double-blind study Arch Phys Med Rehabil 71 1990 24 26 (Pubitemid 20029483)
74. I. Franco, L. Landau-Dyer, G. Isom-Batz, T. Collett, and E.F. Reda The use of botulinum toxin A injection for the management of external sphincter dyssynergia in neurologically normal children J Urol 178 2007 1775 1779
75. C. Sampaio, J. Costa, and J.J. Ferreira Clinical comparability of marketed formulations of botulinum toxin Mov Disord 19 Suppl 8 2004 S129 S136
76. K. Wohlfarth, T. Sycha, D. Ranoux, H. Naver, and D. Caird Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment? Curr Med Res Opin 25 2009 1573 1584